Emcure Pharmaceuticals: For approval of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year…
Emcure Pharmaceuticals (EMCURE) filed a disclosure titled "For approval of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026". The company is valued at about ₹35,726 crore.
What happened
Emcure Pharmaceuticals (EMCURE) filed a disclosure with the exchanges on 3 November 2026 at 01:41 PM titled "For approval of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026".
Company snapshot
Emcure Pharmaceuticals is a mid-cap company in the Healthcare sector, with a market value of about ₹35,726 crore.
The stock last traded at ₹1,883.5, against a 52-week range of ₹1,306.5–₹2,100.7 (10.3% below the high).
Before this filing the shares had moved −3.1% over the month and −4.4% over three months. Average daily turnover over the last 20 sessions was about ₹18.55 crore.
Promoters held 77.83% at the end of Q1 FY27, down 0.04% points from the previous quarter; 0.04% of promoter shares were pledged. Foreign institutions owned 4.88% and domestic institutions 8.46%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 2,101 | 207 | 10.92 |
| Q2 FY26 | 2,270 | 243.5 | 12.85 |
| Q3 FY26 | 2,363 | 230.5 | 12.16 |
| Q4 FY26 | 2,470 | 243.4 | 12.84 |
| Q1 FY27 | 2,580 | 294 | 15.5 |
What history shows
BCEIE's records show 1 previous results filing from the company since May 2026.
Across 300 similar disclosures by other Healthcare companies, shares moved +1.3% on average the next day and +1.9% over five days; 57% of them rose the next day.
Market-wide, 10,321 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 3 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Emcure Pharmaceuticals Limited Estimates – NSE:EMCURE
- Emcure Pharmaceuticals Limited IPO GMP Today, Expected Listing Gain & Price Band
- Emcure Pharmaceuticals Limited (EMCURE.BO) Seasonal returns chart
- Emcure Pharmaceuticals - MFs raise stake for 3 straight quarters in 5 mid-cap stocks; shares gain up to 75% YTD
- Emcure Pharmaceuticals (EMCURE.NS) Holds Near ₹1866.0 as Traders Watch ₹1959.3 Resistance - Triple Top
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.